Clinical trial
Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic…
NCT00071487 · Human Genome Sciences Inc., Industry · Completed
Key facts
| NCT number | NCT00071487 |
|---|---|
| Title | Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE) |
| Official title | A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Systemic Lupus Erythematosus (SLE) |
| Lead sponsor | Human Genome Sciences Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lupus Erythematosus, Systemic |
| Intervention type | Drug |
| Interventions | Placebo, Belimumab 1 mg/kg, Belimumab 4 mg/kg, Belimumab 10 mg/kg |
| Enrollment | 449 |
| Start date | Oct 1, 2003 |
| Primary completion | Aug 1, 2005 |
| Completion | Jun 1, 2006 |
| First posted | Oct 28, 2003 |
| Last update posted | Aug 7, 2013 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: